EGFR and non-small cell lung carcinoma: In part 1a of the phase III CheckMate 227 trial, previously untreated patients with advanced NSCLC (EGFR/ALK wild-type) and PD-L1 ≥1% were randomized (1:1:1) to nivolumab plus ipilimumab, nivolumab alone or chemotherapy alone (47).